日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis.

TOMM20 通过氧化磷酸化、维持还原状态和抵抗细胞凋亡来驱动癌症的侵袭性

Islam Ranakul, Roche Megan E, Lin Zhao, Whitaker-Menezes Diana, Diaz-Barros Victor, Serrano Eurico, Martinez Cantarin Maria Paula, Philp Nancy J, Basu Mallick Atrayee, Martinez-Outschoorn Ubaldo

Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma

磁共振引导立体定向放射治疗复发性胰腺腺癌患者的早期疗效

Poiset, Spencer J; Shah, Sophia; Cappelli, Louis; Anné, Pramila; Mooney, Karen E; Werner-Wasik, Maria; Laufer, Talya S; Posey, James A; Lin, Daniel; Basu Mallick, Atrayee; Lavu, Harish; Bashir, Babar; Yeo, Charles J; Mueller, Adam C

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial

MUC5AC抗体(NPC-1C)联合二线吉西他滨和白蛋白紫杉醇治疗对晚期胰腺导管腺癌患者生存的影响:一项随机临床试验

Huffman, Brandon M; Basu Mallick, Atrayee; Horick, Nora K; Wang-Gillam, Andrea; Hosein, Peter Joel; Morse, Michael A; Beg, Muhammad Shaalan; Murphy, Janet E; Mavroukakis, Sharon; Zaki, Anjum; Schlechter, Benjamin L; Sanoff, Hanna; Manz, Christopher; Wolpin, Brian M; Arlen, Philip; Lacy, Jill; Cleary, James M

A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report

一例罕见的伴有TSC2突变的转移性肠系膜恶性PEComa,采用姑息性手术切除和纳米白蛋白结合型西罗莫司治疗:病例报告

Meredith, Luke; Chao, Timothy; Nevler, Avinoam; Basu Mallick, Atrayee; Singla, Rajan K; McCue, Peter A; Bowne, Wilbur B; Jiang, Wei

Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy for a Cancer Diagnosis

胰十二指肠切除术后非酒精性脂肪肝病(诊断为癌症)

McGhee-Jez, Amy E; Chervoneva, Inna; Yi, Misung; Ahuja, Amisha; Nahar, Ritu; Shah, Samik; Loh, Rebecca; Houtmann, Sarah; Shah, Rashesh; Yeo, Charles J; Lavu, Harish; Cohen, Steven J; Halegoua-DeMarzio, Dina; Basu Mallick, Atrayee